汉莎酶疗法在罕见肾病三期试验中失败
Hansa’s enzyme therapy flunks Phase 3 trial in rare kidney disease
生物技术与制药领域的最新动态
Hansa’s enzyme therapy flunks Phase 3 trial in rare kidney disease
Agilent Technologies opens India Refurbishment Center to advance sustainable science and affordable innovation - Pharmabiz.com
Agilent Technologies Opens India Refurbishment Center at LEED Platinum Facility in Manesar - geneonline.com
ARS Wealth Advisors Group LLC Grows Position in Thermo Fisher Scientific Inc. $TMO - MarketBeat
Assenagon Asset Management S.A. Buys 573,743 Shares of Thermo Fisher Scientific Inc. $TMO - MarketBeat
BioMEMS Market Hits New High | Major Giants Agilent - openPR.com
Top Exec Sells Illumina Shares in a Surprising Move! - TipRanks
GSK wins FDA approval for long-acting asthma drug
Harbour makes $90M upfront deal with Bristol Myers for new antibodies
Nektar claims phase 2 alopecia success after excluding patients who ‘should never have been enrolled’
An increase of NPY1 expression leads to inhibitory phosphorylation of PIN-FORMED (PIN) proteins and suppression of pinoid (pid) null mutants
An in vitro human vessel model to study Neisseria meningitidis colonization and vascular damages
Extracellular adenosine deamination primes tip organizer development in Dictyostelium
On CA1 ripple oscillations in rats and the reassessment of asynchronicity evidence
Endothelial Slit2 guides the Robo1-positive sympathetic innervation during heart development
Multi-gradient permutation survival analysis identifies mitosis and immune signatures steadily associated with cancer patient prognosis
Scott Davies Sells 323 Shares of Illumina (NASDAQ:ILMN) Stock - MarketBeat
Agilent Technologies: What the Next Instrument Cycle Looks Like—Inside the LC & LC/MS Modernization Tailwind! - Smartkarma
Developing a path forward in cancer cachexia
DBV charts new path to market peanut allergy patch after Phase 3 success